Is ixazomib a chemotherapy drug or a targeted drug?

Ixazomib, as a drug that plays an important role in the treatment of multiple myeloma, often attracts people’s attention as to its classification issue—whether it is a chemotherapy drug or a targeted drug. In fact, ixazomib is classified as a targeted drug.

Targeted drugs, as the name suggests, are drugs that target specific molecules or signaling pathways in tumor cells. They usually have good selectivity and can accurately attack tumor cells while having relatively little impact on normal cells. Ixazomib blocks the normal metabolism and decomposition mechanism of cancer cells by inhibiting the intracellular proteasome function, a specific molecule in tumor cells, thereby triggering the apoptosis of cancer cells. This mechanism is completely different from the way chemotherapy drugs kill cells by damaging their DNA, which reflects the high selectivity and precision of targeted drugs.

From a clinical application perspective, ixazomib has demonstrated significant efficacy in the treatment of multiple myeloma. It can not only prolong the survival period of patients, but also improve their quality of life. At the same time, compared with chemotherapy drugs, ixazomib has relatively mild side effects and is easier for patients to tolerate.

However, it is worth noting that although ixazomib is a targeted drug, its use still needs to be under the guidance of a doctor. Patients should pay close attention to their body reactions during use and communicate with their doctor in time if they experience any discomfort. Doctors will adjust the treatment plan based on the patient's specific situation and the severity of side effects to ensure the safety and effectiveness of the treatment.

In summary, ixazomib, as a targeted drug, plays an important role in the treatment of multiple myeloma. Its emergence provides new treatment options for patients and more precise treatment methods for doctors.